Katerina Grafanaki

Dr. Katerina Grafanaki

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KGKaterina Grafanaki
Katerina Grafanaki
ABAngeliki Bania
Angeliki Bania
EKEleni Kaliatsi
Eleni Kaliatsi
EVEleftheria Vryzaki
Eleftheria Vryzaki
Yiannis VASILOPOULOSYiannis VASILOPOULOS
Yiannis VASILOPOULOS
SGSophia Vasileios Georgiou
Sophia Vasileios Georgiou
Atopic dermatitis (AD) is a chronic inflammatory skin condition that affects more than 200 million people worldwide, including up to 20% of children and 10% of the adult population. Although AD appears frequently in childhood and often continues into adulthood, about 1 in 4 adults develop the adult-onset disease. The prenatal period, early childhood, and adolescence are considered critical timepoints for the development of AD when the exposome results in long-lasting effects on the immune system. The exposome can be defined as the measure of all the exposures of an individual during their lifetime and how these exposures relate to well-being. While genetic factors could partially explain AD onset, multiple external environmental exposures (external exposome) in early life are implicated and are equally important for understanding AD manifestation. In this review, we describe the conceptual framework of the exposome and its relevance to AD from conception and across the lifespan. Through a spatiotemporal lens that focuses on the multi-level phenotyping of the environment, we highlight a framework that embraces the dynamic complex nature of exposome and recognizes the influence of additive and interactive environmental exposures. Moreover, we highlight the need to understand the developmental origins of AD from an age-related perspective when studying the effects of the exposome on AD, shifting the research paradigm away from the per se categorized exposome factors and beyond clinical contexts to explore the trajectory of age-related exposome risks and hence future preventive interventions.

Verified
Journal Article
Open access
PDF file
AKAigli Korfiati
Aigli Korfiati
KGKaterina Grafanaki
Katerina Grafanaki
George KyriakopoulosGeorge Kyriakopoulos
George Kyriakopoulos
ISIlias Skeparnias
Ilias Skeparnias
SGSophia Georgiou
Sophia Georgiou
Constantinos STATHOPOULOSConstantinos STATHOPOULOS
Constantinos STATHOPOULOS
The diagnostic and prognostic value of miRNAs in cutaneous melanoma (CM) has been broadly studied and supported by advanced bioinformatics tools. From early studies using miRNA arrays with several limitations, to the recent NGS-derived miRNA expression profiles, an accurate diagnostic panel of a comprehensive pre-specified set of miRNAs that could aid timely identification of specific cancer stages is still elusive, mainly because of the heterogeneity of the approaches and the samples. Herein, we summarize the existing studies that report several miRNAs as important diagnostic and prognostic biomarkers in CM. Using publicly available NGS data, we analyzed the correlation of specific miRNA expression profiles with the expression signatures of known gene targets. Combining network analytics with machine learning, we developed specific non-linear classification models that could successfully predict CM recurrence and metastasis, based on two newly identified miRNA signatures. Subsequent unbiased analyses and independent test sets (i.e., a dataset not used for training, as a validation cohort) using our prediction models resulted in 73.85% and 82.09% accuracy in predicting CM recurrence and metastasis, respectively. Overall, our approach combines detailed analysis of miRNA profiles with heuristic optimization and machine learning, which facilitates dimensionality reduction and optimization of the prediction models. Our approach provides an improved prediction strategy that could serve as an auxiliary tool towards precision treatment.

9 August 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
CACharalabos Antonatos
Charalabos Antonatos
KGKaterina Grafanaki
Katerina Grafanaki
PAPaschalia Asmenoudi
Paschalia Asmenoudi
PXPanagiotis Xiropotamos
Panagiotis Xiropotamos
PNParaskevi Nani
Paraskevi Nani
Yiannis VASILOPOULOSYiannis VASILOPOULOS
Yiannis VASILOPOULOS
Despite the increasing research and clinical interest in the predisposition of psoriasis, a chronic inflammatory skin disease, the multitude of genetic and environmental factors involved in its pathogenesis remain unclear. This complexity is further exacerbated by the several cell types that are implicated in Psoriasis’s progression, including keratinocytes, melanocytes and various immune cell types. The observed interactions between the genetic substrate and the environment lead to epigenetic alterations that directly or indirectly affect gene expression. Changes in DNA methylation and histone modifications that alter DNA-binding site accessibility, as well as non-coding RNAs implicated in the post-transcriptional regulation, are mechanisms of gene transcriptional activity modification and therefore affect the pathways involved in the pathogenesis of Psoriasis. In this review, we summarize the research conducted on the environmental factors contributing to the disease onset, epigenetic modifications and non-coding RNAs exhibiting deregulation in Psoriasis, and we further categorize them based on the under-study cell types. We also assess the recent literature considering therapeutic applications targeting molecules that compromise the epigenome, as a way to suppress the inflammatory cutaneous cascade.

Verified
Journal Article
Open access
PDF file
KGKaterina Grafanaki
Katerina Grafanaki
CACharalabos Antonatos
Charalabos Antonatos
AMAlexandros Maniatis
Alexandros Maniatis
APAntonia Petropoulou
Antonia Petropoulou
EVEleftheria Vryzaki
Eleftheria Vryzaki
Stamatis GregoriouStamatis Gregoriou
Stamatis Gregoriou
Atopic dermatitis (AD) or atopic eczema is an increasingly manifested inflammatory skin disorder of complex etiology which is modulated by both extrinsic and intrinsic factors. The exposome includes a person’s lifetime exposures and their effects. We recently reviewed the extrinsic exposome’s environmental risk factors that contribute to AD. The periods of pregnancy, infancy, and teenage years are recognized as crucial stages in the formation of AD, where the exposome leads to enduring impacts on the immune system. However, research is now focusing on the interactions between intrinsic pathways that are modulated by the extrinsic exposome, including genetic variation, epigenetic modifications, and signals, such as diet, stress, and microbiome interactions. As a result, immune dysregulation, barrier dysfunction, hormonal fluctuations, and skin microbiome dysbiosis are important factors contributing to AD development, and their in-depth understanding is crucial not only for AD treatment but also for similar inflammatory disorders.

30 October 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
DFDavide Fattore
Davide Fattore
ZAZoe Apalla
Zoe Apalla
AFAzael Freites‐Martinez
Azael Freites‐Martinez
NTNello Tommasino
Nello Tommasino
VNVasiliki A. Nikolaou
Vasiliki A. Nikolaou
VSVincent Sibaud
Vincent Sibaud

26 October 2024 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
ZAZoe Apalla
Zoe Apalla
AFA. Freites‐Martinez
A. Freites‐Martinez
KGKaterina Grafanaki
Katerina Grafanaki
AOA. Ortiz‐Brugues
A. Ortiz‐Brugues
VNVasiliki A. Nikolaou
Vasiliki A. Nikolaou
VSV. Sibaud
V. Sibaud
Background: There is a need for unified guidance in the management of acneiform rash induced by epidermal growth factor receptor inhibitors (EGFRi) among dermatologists.Objective: To establish unified international guidelines for the management of acneiform rash caused by EGFR inhibitors, based on an experts' Delphi consensus.Methods: The initiative was led by five members of the European Academy of Dermatology and Venereology Task Force ‘Dermatology for Cancer Patients’ who developed a questionnaire that was circulated to a group of 32 supportive oncodermatology experts in Europe, Canada, Argentina, the US States and Asia. The questionnaire consisted of 84 statements in total, regarding diagnosis and treatment of EGFRi‐induced acneiform rash. Experts responded to an anonymous 5‐point Likert scale survey. The coordinators collected the first‐round responses that were checked for consensus (≥75% agreement in positive [agree or strongly agree] or in negative [disagree or strongly disagree] vote). The statements that did not reach strong consensus in the first round were revised, according to experts' feedback, for a second‐round survey.Results: Strong consensus was reached in 75/84 (89.3%) of the statements, whilst moderate consensus was achieved in 6/84 elements. Key points include consideration of low‐dose isotretinoin for refractory grade II/III acneiform rash, use of topical steroid‐sparing agents like topical pimecrolimus in the maintenance phase and use of doxycycline in either 100 or 200 mg per day as prophylactic treatment. Interestingly, experts did not recommend topical antibiotics, neither for prevention, nor for treatment. Consensus failure in 3/84 objects is mostly related to the lack of robust data on these topics.Conclusion: This consensus offers crucial insights often overlooked by radiotherapists, general practitioners, dermatologists and oncologists, and it is expected to improve the management of oncologic patients treated with EGFRi in different settings and continents.
1